Molecular Partners (MOLN) Competitors $3.59 +0.03 (+0.84%) Closing price 10/24/2025 03:45 PM EasternExtended Trading$3.58 0.00 (-0.14%) As of 10/24/2025 04:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock MOLN vs. GLUE, SIGA, MLTX, ARCT, OPT, KALV, NAGE, ESPR, BCYC, and CMPXShould you be buying Molecular Partners stock or one of its competitors? The main competitors of Molecular Partners include Monte Rosa Therapeutics (GLUE), Siga Technologies (SIGA), MoonLake Immunotherapeutics (MLTX), Arcturus Therapeutics (ARCT), Opthea (OPT), KalVista Pharmaceuticals (KALV), Niagen Bioscience (NAGE), Esperion Therapeutics (ESPR), Bicycle Therapeutics (BCYC), and Compass Therapeutics (CMPX). These companies are all part of the "pharmaceutical products" industry. Molecular Partners vs. Its Competitors Monte Rosa Therapeutics Siga Technologies MoonLake Immunotherapeutics Arcturus Therapeutics Opthea KalVista Pharmaceuticals Niagen Bioscience Esperion Therapeutics Bicycle Therapeutics Compass Therapeutics Monte Rosa Therapeutics (NASDAQ:GLUE) and Molecular Partners (NASDAQ:MOLN) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their valuation, dividends, risk, media sentiment, institutional ownership, earnings, profitability and analyst recommendations. Which has stronger earnings and valuation, GLUE or MOLN? Molecular Partners has lower revenue, but higher earnings than Monte Rosa Therapeutics. Molecular Partners is trading at a lower price-to-earnings ratio than Monte Rosa Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioMonte Rosa Therapeutics$75.62M9.10-$72.70M$0.3630.94Molecular Partners$5.65M25.66-$61.39M-$2.08-1.73 Is GLUE or MOLN more profitable? Monte Rosa Therapeutics has a net margin of 13.58% compared to Molecular Partners' net margin of 0.00%. Monte Rosa Therapeutics' return on equity of 9.95% beat Molecular Partners' return on equity.Company Net Margins Return on Equity Return on Assets Monte Rosa Therapeutics13.58% 9.95% 6.42% Molecular Partners N/A -50.66%-45.13% Which has more volatility & risk, GLUE or MOLN? Monte Rosa Therapeutics has a beta of 1.54, suggesting that its stock price is 54% more volatile than the S&P 500. Comparatively, Molecular Partners has a beta of 1.09, suggesting that its stock price is 9% more volatile than the S&P 500. Does the media refer more to GLUE or MOLN? In the previous week, Monte Rosa Therapeutics had 1 more articles in the media than Molecular Partners. MarketBeat recorded 3 mentions for Monte Rosa Therapeutics and 2 mentions for Molecular Partners. Molecular Partners' average media sentiment score of 0.95 beat Monte Rosa Therapeutics' score of 0.88 indicating that Molecular Partners is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Monte Rosa Therapeutics 0 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Molecular Partners 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts prefer GLUE or MOLN? Monte Rosa Therapeutics currently has a consensus target price of $15.33, suggesting a potential upside of 37.64%. Molecular Partners has a consensus target price of $8.00, suggesting a potential upside of 122.84%. Given Molecular Partners' higher probable upside, analysts plainly believe Molecular Partners is more favorable than Monte Rosa Therapeutics.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Monte Rosa Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25Molecular Partners 1 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Do institutionals & insiders believe in GLUE or MOLN? 80.0% of Monte Rosa Therapeutics shares are held by institutional investors. Comparatively, 26.6% of Molecular Partners shares are held by institutional investors. 6.9% of Monte Rosa Therapeutics shares are held by insiders. Comparatively, 5.9% of Molecular Partners shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. SummaryMonte Rosa Therapeutics beats Molecular Partners on 12 of the 16 factors compared between the two stocks. Get Molecular Partners News Delivered to You Automatically Sign up to receive the latest news and ratings for MOLN and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding MOLN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart MOLN vs. The Competition Export to ExcelMetricMolecular PartnersMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$143.73M$3.43B$6.24B$10.65BDividend YieldN/A2.27%5.71%4.82%P/E Ratio-1.7325.8530.6130.44Price / Sales25.66514.92596.73191.77Price / CashN/A45.5737.0161.44Price / Book0.9010.4012.036.60Net Income-$61.39M-$52.72M$3.32B$276.82M7 Day Performance-5.40%2.10%1.89%2.55%1 Month Performance-3.62%12.33%7.71%3.76%1 Year Performance-44.68%14.14%56.33%33.04% Molecular Partners Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)MOLNMolecular Partners1.6555 of 5 stars$3.59+0.8%$8.00+122.8%-40.4%$143.73M$5.65M-1.73180News CoverageUpcoming EarningsGLUEMonte Rosa Therapeutics2.4736 of 5 stars$9.59-2.8%$15.33+59.9%+128.7%$609.57M$75.62M26.6490News CoverageSIGASiga Technologies2.1349 of 5 stars$8.47-0.1%N/A+28.1%$607.22M$138.72M7.5040Positive NewsMLTXMoonLake Immunotherapeutics2.8943 of 5 stars$9.16-2.0%$36.00+293.0%-79.4%$600.88MN/A-3.292Trending NewsARCTArcturus Therapeutics3.4575 of 5 stars$23.16+7.7%$50.57+118.4%-40.9%$584.09M$152.31M-10.39180Trending NewsAnalyst DowngradeAnalyst RevisionHigh Trading VolumeOPTOpthea0.4522 of 5 stars$3.41+7.2%$1.33-60.9%-18.8%$583.10M$30K0.008News CoverageGap UpHigh Trading VolumeKALVKalVista Pharmaceuticals3.8146 of 5 stars$11.43-1.0%$26.43+131.2%-7.8%$583.04M$1.43M-2.90100NAGENiagen Bioscience2.2923 of 5 stars$7.51+4.2%$13.42+78.7%N/A$575.02M$116.30M35.76120ESPREsperion Therapeutics3.7315 of 5 stars$2.79-1.1%$7.00+150.9%+31.6%$568.58M$268.13M-5.69200BCYCBicycle Therapeutics3.4248 of 5 stars$8.29+1.6%$22.22+168.1%-68.2%$565.54M$35.28M-2.36240Upcoming EarningsCMPXCompass Therapeutics2.3999 of 5 stars$4.10+1.2%$13.10+219.5%+125.6%$560.04M$850K-9.1120Analyst Forecast Related Companies and Tools Related Companies Monte Rosa Therapeutics Competitors Siga Technologies Competitors MoonLake Immunotherapeutics Competitors Arcturus Therapeutics Competitors Opthea Competitors KalVista Pharmaceuticals Competitors Niagen Bioscience Competitors Esperion Therapeutics Competitors Bicycle Therapeutics Competitors Compass Therapeutics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:MOLN) was last updated on 10/25/2025 by MarketBeat.com Staff From Our PartnersNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredIf You Keep Cash In A U.S. Bank Account… Read This NOWThe Treasury Department just issued a stunning warning: U.S. banks could lose up to $6.6 trillion of custom...Banyan Hill Publishing | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredClaim Your Share of $5.39 BILLION in AI Equity ChecksThe U.S. government just took advantage of Public Law 81-774 to crack down on AI companies... In turn, enfo...Angel Publishing | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredBuy UBER immediatelyBULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Molecular Partners AG Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Molecular Partners With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free MOLN Stock Alerts